> Encouraging trials of MeRes100, first bioresorbable vascular matrix to treat CAD
MeRes100, used for the treatment of de-novo coronary artery lesions, has demonstrated zero scaffold thrombosis and very low Major Adverse Cardiac Event (MACE) rates for patients with coronary artery disease.
News provided by Meril Life Sciences (extract):
Meril's recently CE-approved MeRes100TM, used for the treatment of de-novo coronary artery lesions, has demonstrated zero scaffold thrombosis and very low Major Adverse Cardiac Event (MACE) rate of 1.87% at three years as shown in MeRes-1 and 1.61% in MeRes-1 Extend at two years.
"First generation bioresorbable scaffolds have not shown the most favourable results at long term. MeRes100, a next generation bioresorbable scaffold, has been developed with reduced strut thickness, an improved profile for better deliverability, faster degradation and possibly lower scaffold thrombosis" said principal investigator for the MeRes-1 trial Dr Ashok Seth, Chairman of Fortis Escorts Heart Institute in New Delhi, India.